Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been demonstrated to be clinically useful against COVID-19, but viral resistance to the drug was found to arise readily via multiple pathways in vitro.
- Sho Iketani
- Hiroshi Mohri
- David D. Ho